Abo-Amer Yousry Esam-Eldin, Mohamed Amal Ahmed, Elhoseeny Mohamed Mahmoud, Rezk Samar M, Abdel-Salam Sherief, Alrohaimi Abdulmohsen H, Abdelgeliel Asmaa Sayed, Alzahrani Seham Saeed, Jafri Ibrahim, Alqahtani Leena S, Fayad Eman, Fakhry Mohamed, Soliman Moataz Yousry
Mahala Hepatology Teaching Hospital, Hepatology& Gastroenterology Department, Gharbia, Elgharbia, Egypt.
National Hepatology & Tropical Medicine Research Institute, Department of Biochemistry, Cairo, Egypt.
Infect Drug Resist. 2023 Jul 8;16:4463-4469. doi: 10.2147/IDR.S414186. eCollection 2023.
BACKGROUND & AIMS: This research aimed to determine how variations in the vitamin D receptor gene affected the response of infections to eradication therapy.
On 105 adult -positive patients, a prospective cohort study was carried out. PCR was used to genotype all patients' VDR gene polymorphisms. The patients in the study received standard triple eradication medication (clarithromycin 500 mg, amoxicillin 1000 mg, and omeprazole 20 mg) twice daily for 14 days. A stool test for Ag was conducted 4 weeks following the end of treatment.
In our study, the usual triple therapy's eradication rate was 75.2%. The successful eradication of H. pylori and VDR rs 2228570 gene polymorphisms was more prevalent in CT gene polymorphism (64.6%) compared to non-responders (19.2%), while treatment failure was more prevalent in CC gene polymorphism (73.1% in non-responders compared to responders 24.1%), which is statistically significant. In regards to the eradication of and VDR rs7975232 gene polymorphisms, the success of eradication was more prevalent in AC gene polymorphism (54.4%) vs non-responders (30.4%), while all patients (14) with gene AA (17.7%) are responders to standard treatment, while the failure of treatment was more prevalent in CC gene polymorphism (69.2% in non-responder vs 27.8% in responders) which is statistically significant. Our findings demonstrated a strong correlation between patients' responses to treatment and polymorphisms in the VDR gene (ApaI and TaqI) (P 0.05).
As far as we are aware, this is the first study to identify a potential link between the FokI and Apal VDR polymorphism and treatment response in -positive patients. To evaluate the findings, more research with larger number of patients and different population is required.
本研究旨在确定维生素D受体基因的变异如何影响感染对根除治疗的反应。
对105例成年阳性患者进行了一项前瞻性队列研究。采用聚合酶链反应（PCR）对所有患者的维生素D受体（VDR）基因多态性进行基因分型。研究中的患者接受标准三联根除药物治疗（克拉霉素500毫克、阿莫西林1000毫克和奥美拉唑20毫克），每日两次，共14天。治疗结束4周后进行粪便抗原检测。
在我们的研究中，常规三联疗法的根除率为75.2%。与未应答者（19.2%）相比，幽门螺杆菌的成功根除和VDR rs2228570基因多态性在CT基因多态性中更为普遍（64.6%），而治疗失败在CC基因多态性中更为普遍（未应答者中为73.1%，应答者中为24.1%），具有统计学意义。关于幽门螺杆菌根除和VDR rs7975232基因多态性，根除成功在AC基因多态性中更为普遍（54.4%），而未应答者为（30.4%），而所有携带AA基因的患者（14例，占17.7%）对标准治疗有应答，而治疗失败在CC基因多态性中更为普遍（未应答者中为69.2%，应答者中为27.8%），具有统计学意义。我们的研究结果表明患者对治疗的反应与VDR基因（ApaI和TaqI）多态性之间存在很强的相关性（P<0.05）。
据我们所知，这是第一项确定FokI和Apal VDR多态性与阳性患者治疗反应之间潜在联系的研究。为了评估这些发现，需要对更多患者和不同人群进行更多研究。
